Inflammatory Bowel Diseases Clinical Trial
— OVI-IBDOfficial title:
Oral Versus Intravenous Iron in IBD Patients With Anti-inflammatory Therapy
NCT number | NCT05581420 |
Other study ID # | NL79363.058.21 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | June 2, 2022 |
Est. completion date | May 2025 |
Rationale: Iron deficiency anemia is the most common systemic manifestation of Inflammatory Bowel Diseases (IBD)-Crohn's disease and ulcerative colitis. Iron deficiency with or without anemia poses a diagnostic and therapeutic challenge due to chronic gastrointestinal blood loss and the inflammatory nature of IBD. Oral iron supplementation in active disease states is controversial. Hepcidin levels can be considered as the sum effect of all regulatory processes. Studies suggested that iron stores and hypoxia reduce hepcidin levels even in an inflammatory state. This is also reflected by a study which demonstrated low levels of hepcidin in patients with ferritin levels under 30μg/ml, regardless of disease activity or type. Furthermore, studies show that immunosuppressive medication decrease the level of hepcidin. This raises the question: is oral iron a viable alternative for patients under immunosuppressive treatment for active IBD? Objective: The hypothesis is that patients with mild to moderate IBD activity on immunosuppressive medication, show the same level of Hb increase after 12 weeks after either oral or iv iron supplementation, while the price of oral iron supplementation is significantly lower.
Status | Recruiting |
Enrollment | 152 |
Est. completion date | May 2025 |
Est. primary completion date | May 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Established IBD diagnosis (Crohn's disease, ulcerative colitis, IBD-unclassified) - Adults (=18 years of age) - Any single Hb level between 6,2 - 7,3 mmol/L (females) 6,2 - 8,0 mmol/L (males) - Any single ferritin <100 µg/L and transferrin saturation <20% within 4 weeks of study inclusion - CRP > 5 mg/L and / or fecal calprotectin > 150 within 4 weeks of randomization - Patients on immunosuppressive medication (thiopurine, methotrexate, biologicals, JAK inhibitor) for at least 8 weeks or if prednisone, for at least 2 weeks - Mild to moderate disease according to the treating physician; a Physician Global Assessment (PGA) score of 1 or 2 - Documented informed consent Exclusion Criteria: - Anemia due to reasons other than iron deficiency or chronic disease (e.g. hemoglobinopathy). - Severe disease with a PGA score of 3 - IBD patients with a location of IBD at other places than ileum and / or colon (according to treating physician) - Patients who are prescribed PPI - Earlier significant side effect of oral iron or iv iron - Folic acid deficiency (<2.5 µg/ml) - Vitamin B12 deficiency (<150 mg/l) - Patients can proceed with their regular diet, but during the study they cannot take supplements that contain iron. For example, commercial vitamins with iron or a well-known iron supplement Floradix®. Intake of said supplements must be stopped at the moment of inclusion. - Documented history of bariatric surgery or gastric/duodenal resections due to benign or malignant pathologies - Documented major operation (e.g., laparotomy) less than six weeks before inclusion - Documented history of liver cirrhosis, heart failure, hemoglobinopathies, autoimmune hemolytic anemia, myelodysplastic syndrome, or chronic obstructive pulmonary disease (COPD) - Documented history of recent treatment for a malignancy (excluding dermatological malignancies such as basal cell carcinoma or squamous cell carcinoma). Patients can be included if the treatment for malignancy has been finalized =6 months before the inclusion date. - End-stage renal disease (impaired renal function, defined as eGFR <30 ml/min/1.73m2) - Documented pregnancy or breastfeeding at the time of inclusion |
Country | Name | City | State |
---|---|---|---|
Netherlands | Leiden University Medical Centre | Leiden | Zuid-Holland |
Lead Sponsor | Collaborator |
---|---|
Leiden University Medical Center | Adrz, Goes, Erasmus Medical Center, Medical Center Haaglanden, Rijnstate Hospital, Sint Franciscus Gasthuis, UMC Utrecht, University Medical Center Groningen |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Normalization of Hb concentration (> 7.3 mmol/L (females) or > 8.0 mmol/L (males)) from baseline to week 12 in both oral and iv iron supplementation group. | Percentage of patients who achieved an adequate hematologic response (defined by Hb > 7.3 mmol/L (females) or > 8.0 mmol/L (males)) after 12 weeks | After 12 weeks | |
Secondary | Change in Hb levels | Change in Hb levels from baseline to weeks 4, 12, and 16 in both both oral and iv iron supplementation group. | baseline, weeks 4, 12 and 16 | |
Secondary | percentage of participants with ferritin levels > 100 microg/l | Percentage of patients who achieve ferritin levels > 100 microg/l in both both oral and iv iron supplementation group. | after 4, 12 and 16 weeks | |
Secondary | Preference of patient for oral versus i.v. iron | percentage of patients who prefer oral or i.v. iron supplementation | at baseline and at week 16 | |
Secondary | Change in Disease-specific Quality of life (IBDQ) | Change in health related quality of life (measured by the sIBDQ) measuring physical, social, and emotional status (score 10-70, poor to good HRQoL) from baseline to week 16 in both both oral and iv iron supplementation group. | at week 16 in comparison with baseline | |
Secondary | Change in overall/generic Quality of life (EQ-5D-5L) | Change in overall/generic quality of life from baseline to week 16 in both oral and iv iron supplementation group. This is measured by the EQ-5D-5L generating a 5-digit number that describes the patient's health state and a VAS that can be used as a quantitative measure of health outcome that reflect the patient's own judgement. | at week 16 in comparison with baseline | |
Secondary | Change in productivity cost (iPCQ) | Change in productivity cost (measured by the iPCQ) from baseline to week 16 in both both oral and iv iron supplementation group. To calculate the cost of productivity losses, volumes are multiplied by unit cost prices. | at baseline and week 16 | |
Secondary | Change in medical consumption use (iMCQ) | Change in medical consumption use (measured by the iMCQ) from baseline to week 16 in both both oral and iv iron supplementation group. The costs of medical consumption are calculated by multiplying measured volumes of care by the cost per unit of care. | at baseline and week 16 | |
Secondary | Therapy adherence measured with the modified MMAS-8 for patients in the oral iron group | Therapy adherence measured with the modified MMAS-8 for patients in the oral iron group. Scores of 8 points, <8 to >6 points and =6 points are considered to have high, medium and low adherence, respectively. | at week 4, 8, 12 and at week 16 if patients still use iron according to the protocol | |
Secondary | Correlation between response to iron therapy and disease activity | he correlation of disease activity (evaluated by fecal calprotectin levels and c-reactive protein levels) and response to iron therapy in both oral and iv iron supplementation group. | At week 4, 12 and 16 | |
Secondary | Incidence of hypophosphatemia during iron therapy | Percentage of patients who experienced hypophosphatemia throughout iron therapy in both oral and iv iron supplementation group. | At week 4, 12 and 16 | |
Secondary | Number of (serious) adverse events and adverse reactions according to MedDRA criteria. | Number of (serious) adverse events and adverse reactions according to MedDRA criteria throughout the study period. | From baseline until week 16 | |
Secondary | Change in clinical disease activity | Change in clinical disease activity (measured by mobile Health Index (mHI) 0-24 for patients with Crohn's disease and 0-34 for patients with ulcerative colitis; higher scores indicate a more active disease) 16 in both oral and iv iron supplementation group from baseline to week 16. | baseline, weeks 4, 12 and 16 | |
Secondary | Hepcidin - and soluble Transferrin Receptor (sTfR) - fecal calprotectin / CRP ratio | at baseline and week 12 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04046913 -
The ADDapt Diet in Reducing Crohn's Disease Inflammation
|
N/A | |
Active, not recruiting |
NCT04989907 -
A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Switzerland
|
||
Recruiting |
NCT05316584 -
A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy
|
N/A | |
Active, not recruiting |
NCT04990258 -
A 24-month Real Life PErsistence Efficacy and Safety Study in IBD Patients in REMission Switched From Intravenous Infliximab to Subcutaneous Infliximab CT-P13 Remsima®SC
|
||
Completed |
NCT06216223 -
Laser Versus Surgery in Anal Diseases in Inflammatory Bowel Patients
|
N/A | |
Enrolling by invitation |
NCT06015789 -
Self-care in Patients Affected by Inflammatory Bowel Disease and Caregivers' Contribution to Self-care
|
||
Recruiting |
NCT06065995 -
StoMakker Mobile Application
|
N/A | |
Recruiting |
NCT03282786 -
Comparison of Carbon Dioxide (CO2) to Air Insufflation in Colonoscopy in Patients With Inflammatory Bowel Disease
|
N/A | |
Recruiting |
NCT06002074 -
SMART Program Impact on Quality of Life in Inflammatory Bowel Diseases
|
N/A | |
Recruiting |
NCT04960826 -
Study of an Environmental Risk Factor in Crohn's Disease
|
||
Recruiting |
NCT05413941 -
Internet-based Cognitive Behavioral Therapy in Inflammatory Bowel Disease
|
N/A | |
Completed |
NCT03668249 -
A Study to Characterize Multidimensional Model to Predict the Course of Crohn's Disease (CD)
|
||
Completed |
NCT00721812 -
A First Time In Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK1399686
|
Phase 1 | |
Recruiting |
NCT05809999 -
IBD Neoplasia Surveillance RCT
|
N/A | |
Recruiting |
NCT04138225 -
The Ecological Role of Yeasts in the Human Gut
|
||
Recruiting |
NCT04991324 -
Cholecalciferol Comedication in IBD - the 5C-study
|
Phase 3 | |
Completed |
NCT03173144 -
Chronic Inflammatory Disease, Lifestyle and Treatment Response
|
||
Not yet recruiting |
NCT05043818 -
A Clinical Study on the Screening of Intestinal Biomarkers in IBD Patients With Depression
|
||
Recruiting |
NCT03042091 -
Neomycin and Metronidazole Hydrochloride With or Without Polyethylene Glycol in Reducing Infection in Patients Undergoing Elective Colorectal Surgery
|
Early Phase 1 | |
Not yet recruiting |
NCT02858557 -
The Effect of Diet on Microbial Profile and Disease Outcomes in Patients With Inflammatory Bowel Diseases
|
N/A |